Raymond James Maintains Outperform on Passage Bio, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has maintained an Outperform rating on Passage Bio (NASDAQ:PASG) but has reduced the price target from $9 to $5.

November 14, 2023 | 8:47 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Raymond James has maintained an Outperform rating on Passage Bio but lowered the price target from $9 to $5, indicating a potential downside compared to the previous target.
The reduction in price target by a reputable analyst like Raymond James could lead to a negative investor sentiment in the short term, as it suggests a lower expected future stock price. However, maintaining the Outperform rating indicates that the analyst still sees the company favorably, which might mitigate the negative impact to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100